Validating a sensitive LCMS method for the quantitation of artemisinin in Artemisia spp. including material used in retracted clinical trials

Validating a sensitive LCMS method for the quantitation of artemisinin in Artemisia spp. including material used in retracted clinical trials

•A sensitive LCMS method was developed for the quantitation of artemisinin in Artemisia annua and A. afra.•This method was applied to a collection of Artemisia samples including two A. afra samples used in retracted clinical trials.•No artemisinin could be detected in any A. afra samples except in t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis Vol. 208; p. 114446
Main Authors: Lee, Barend J., van Niekerk, Suzanne E., Legoabe, Lesetja J., van der Kooy, Frank
Format: Journal Article
Language:English
Published: England Elsevier B.V 20-01-2022
Subjects:
Artemisia
Artemisia afra
Artemisia annua
Artemisinin
Artemisinins - analysis
Chromatography, Liquid
Clinical Trials as Topic
Humans
LCMS
Mass Spectrometry
Plant Extracts
Quality control
Young Adult
Artemisia afra
Artemisia annua
LCMS
Artemisinin
Quality control
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A sensitive LCMS method was developed for the quantitation of artemisinin in Artemisia annua and A. afra.•This method was applied to a collection of Artemisia samples including two A. afra samples used in retracted clinical trials.•No artemisinin could be detected in any A. afra samples except in the samples used in the clinical trials.•Quality control of herbal material is of utmost importance to ensure the safety of trial participants. [Display omitted] Two recent clinical trials reported that Artemisia afra contained significant amounts of the bioactive compound artemisinin. We suspected sample contamination and therefore obtained the A. afra material for testing. A sensitive liquid chromatography mass spectrometry method was developed and validated for the accurate quantitation of artemisinin in Artemisia annua and A. afra plant material. This validated analytical method, with a limit of detection of 0.22 ng/mL (0.22 pg on column), which is an order of magnitude more sensitive than recently published methods, was applied to quantify artemisinin in a collection of Artemisia samples including the A. afra material that was used in the clinical trials.All 16A. annua samples (oldest sample 21 years old) contained the expected levels of artemisinin (0.12–0.63%) whilst none of the A. afra samples in our collection contained any trace of artemisinin (> 0.00001%). However, the A. afra samples used in the clinical trials did contain detectable amounts of artemisinin (0.0013% and 0.0011% vs the claimed amount of 0.0045%).The authors of the clinical trials suspected that cross contamination during sample handling and preparation was likely, reconfirming the importance of having analytical quality control methods in place before clinical trials are conducted. Quality control and ensuring safety of trial participants is of utmost importance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2021.114446